Applied DNA Sciences, Inc. (NASDAQ: APDN) Stock Competitors & Peer Comparison
See APDN's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Medical - Diagnostics & Research Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for APDN and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| APDN | $5.62 | +31.62% | 7.3M | -0.10 | -$57.12 | N/A |
| DHR-PB | $1,261.26 | -0.78% | 916.8B | 146.01 | $8.64 | +0.71% |
| TMO | $654.80 | +0.35% | 242.2B | 28.28 | $23.16 | +0.28% |
| DHR | $214.06 | +1.09% | 150.5B | 26.82 | $7.98 | +0.71% |
| NTRA | $410.35 | +0.46% | 58.8B | -310.87 | -$1.32 | N/A |
| A | $167.78 | +0.66% | 47.4B | 28.86 | $5.81 | +0.60% |
| IQV | $258.21 | -0.96% | 42.5B | 21.29 | $12.13 | N/A |
| WAT | $425.21 | -0.08% | 41.7B | 31.08 | $13.68 | N/A |
| ILMN | $273.04 | +2.75% | 41.3B | 54.28 | $5.03 | N/A |
| IDXX | $518.39 | +0.12% | 40.9B | 36.45 | $14.22 | N/A |
Stock Comparison
Danaher Corporation (NYSE: DHR-PB)
APDN vs DHR-PB Comparison October 2026
Applied DNA Sciences, Inc. (NASDAQ: APDN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APDN stands at 7.3M. In comparison, DHR-PB has a market cap of 916.8B. Regarding current trading prices, APDN is priced at $5.62 on the NASDAQ, while DHR-PB trades at $1,261.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APDN currently has a P/E ratio of -0.10, whereas DHR-PB's P/E ratio is 146.01. In terms of profitability, APDN's ROE is -7.23%, compared to DHR-PB's ROE of +0.08%. Regarding short-term risk, APDN is more volatile compared to DHR-PB. This indicates higher risk in terms of short-term price fluctuations for APDN.Check DHR-PB's competition here
Thermo Fisher Scientific Inc. (NYSE: TMO)
APDN vs TMO Comparison October 2026
Applied DNA Sciences, Inc. (NASDAQ: APDN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APDN stands at 7.3M. In comparison, TMO has a market cap of 242.2B. Regarding current trading prices, APDN is priced at $5.62 on the NASDAQ, while TMO trades at $654.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APDN currently has a P/E ratio of -0.10, whereas TMO's P/E ratio is 28.28. In terms of profitability, APDN's ROE is -7.23%, compared to TMO's ROE of +0.13%. Regarding short-term risk, APDN is more volatile compared to TMO. This indicates higher risk in terms of short-term price fluctuations for APDN.Check TMO's competition here
Danaher Corporation (NYSE: DHR)
APDN vs DHR Comparison October 2026
Applied DNA Sciences, Inc. (NASDAQ: APDN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APDN stands at 7.3M. In comparison, DHR has a market cap of 150.5B. Regarding current trading prices, APDN is priced at $5.62 on the NASDAQ, while DHR trades at $214.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APDN currently has a P/E ratio of -0.10, whereas DHR's P/E ratio is 26.82. In terms of profitability, APDN's ROE is -7.23%, compared to DHR's ROE of +0.08%. Regarding short-term risk, APDN is more volatile compared to DHR. This indicates higher risk in terms of short-term price fluctuations for APDN.Check DHR's competition here
Natera, Inc. (NASDAQ: NTRA)
APDN vs NTRA Comparison October 2026
Applied DNA Sciences, Inc. (NASDAQ: APDN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APDN stands at 7.3M. In comparison, NTRA has a market cap of 58.8B. Regarding current trading prices, APDN is priced at $5.62 on the NASDAQ, while NTRA trades at $410.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APDN currently has a P/E ratio of -0.10, whereas NTRA's P/E ratio is -310.87. In terms of profitability, APDN's ROE is -7.23%, compared to NTRA's ROE of -0.12%. Regarding short-term risk, APDN is more volatile compared to NTRA. This indicates higher risk in terms of short-term price fluctuations for APDN.Check NTRA's competition here
Agilent Technologies, Inc. (NYSE: A)
APDN vs A Comparison October 2026
Applied DNA Sciences, Inc. (NASDAQ: APDN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APDN stands at 7.3M. In comparison, A has a market cap of 47.4B. Regarding current trading prices, APDN is priced at $5.62 on the NASDAQ, while A trades at $167.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APDN currently has a P/E ratio of -0.10, whereas A's P/E ratio is 28.86. In terms of profitability, APDN's ROE is -7.23%, compared to A's ROE of +0.20%. Regarding short-term risk, APDN is more volatile compared to A. This indicates higher risk in terms of short-term price fluctuations for APDN.Check A's competition here
IQVIA Holdings Inc. (NYSE: IQV)
APDN vs IQV Comparison October 2026
Applied DNA Sciences, Inc. (NASDAQ: APDN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APDN stands at 7.3M. In comparison, IQV has a market cap of 42.5B. Regarding current trading prices, APDN is priced at $5.62 on the NASDAQ, while IQV trades at $258.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APDN currently has a P/E ratio of -0.10, whereas IQV's P/E ratio is 21.29. In terms of profitability, APDN's ROE is -7.23%, compared to IQV's ROE of +0.22%. Regarding short-term risk, APDN is more volatile compared to IQV. This indicates higher risk in terms of short-term price fluctuations for APDN.Check IQV's competition here
Waters Corporation (NYSE: WAT)
APDN vs WAT Comparison October 2026
Applied DNA Sciences, Inc. (NASDAQ: APDN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APDN stands at 7.3M. In comparison, WAT has a market cap of 41.7B. Regarding current trading prices, APDN is priced at $5.62 on the NASDAQ, while WAT trades at $425.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APDN currently has a P/E ratio of -0.10, whereas WAT's P/E ratio is 31.08. In terms of profitability, APDN's ROE is -7.23%, compared to WAT's ROE of +0.02%. Regarding short-term risk, APDN is more volatile compared to WAT. This indicates higher risk in terms of short-term price fluctuations for APDN.Check WAT's competition here
Illumina, Inc. (NASDAQ: ILMN)
APDN vs ILMN Comparison October 2026
Applied DNA Sciences, Inc. (NASDAQ: APDN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APDN stands at 7.3M. In comparison, ILMN has a market cap of 41.3B. Regarding current trading prices, APDN is priced at $5.62 on the NASDAQ, while ILMN trades at $273.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APDN currently has a P/E ratio of -0.10, whereas ILMN's P/E ratio is 54.28. In terms of profitability, APDN's ROE is -7.23%, compared to ILMN's ROE of +0.31%. Regarding short-term risk, APDN is more volatile compared to ILMN. This indicates higher risk in terms of short-term price fluctuations for APDN.Check ILMN's competition here
IDEXX Laboratories, Inc. (NASDAQ: IDXX)
APDN vs IDXX Comparison October 2026
Applied DNA Sciences, Inc. (NASDAQ: APDN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APDN stands at 7.3M. In comparison, IDXX has a market cap of 40.9B. Regarding current trading prices, APDN is priced at $5.62 on the NASDAQ, while IDXX trades at $518.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APDN currently has a P/E ratio of -0.10, whereas IDXX's P/E ratio is 36.45. In terms of profitability, APDN's ROE is -7.23%, compared to IDXX's ROE of +0.72%. Regarding short-term risk, APDN is more volatile compared to IDXX. This indicates higher risk in terms of short-term price fluctuations for APDN.Check IDXX's competition here
Mettler-Toledo International Inc. (NYSE: MTD)
APDN vs MTD Comparison October 2026
Applied DNA Sciences, Inc. (NASDAQ: APDN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APDN stands at 7.3M. In comparison, MTD has a market cap of 30B. Regarding current trading prices, APDN is priced at $5.62 on the NASDAQ, while MTD trades at $1,486.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APDN currently has a P/E ratio of -0.10, whereas MTD's P/E ratio is 34.17. In terms of profitability, APDN's ROE is -7.23%, compared to MTD's ROE of -12.00%. Regarding short-term risk, APDN is more volatile compared to MTD. This indicates higher risk in terms of short-term price fluctuations for APDN.Check MTD's competition here
Quest Diagnostics Incorporated (NYSE: DGX)
APDN vs DGX Comparison October 2026
Applied DNA Sciences, Inc. (NASDAQ: APDN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APDN stands at 7.3M. In comparison, DGX has a market cap of 25.7B. Regarding current trading prices, APDN is priced at $5.62 on the NASDAQ, while DGX trades at $233.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APDN currently has a P/E ratio of -0.10, whereas DGX's P/E ratio is 23.00. In terms of profitability, APDN's ROE is -7.23%, compared to DGX's ROE of +0.14%. Regarding short-term risk, APDN is more volatile compared to DGX. This indicates higher risk in terms of short-term price fluctuations for APDN.Check DGX's competition here
Labcorp Holdings Inc. (NYSE: LH)
APDN vs LH Comparison October 2026
Applied DNA Sciences, Inc. (NASDAQ: APDN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APDN stands at 7.3M. In comparison, LH has a market cap of 25.3B. Regarding current trading prices, APDN is priced at $5.62 on the NASDAQ, while LH trades at $308.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APDN currently has a P/E ratio of -0.10, whereas LH's P/E ratio is 18.31. In terms of profitability, APDN's ROE is -7.23%, compared to LH's ROE of +0.12%. Regarding short-term risk, APDN is more volatile compared to LH. This indicates higher risk in terms of short-term price fluctuations for APDN.Check LH's competition here
Guardant Health, Inc. (NASDAQ: GH)
APDN vs GH Comparison October 2026
Applied DNA Sciences, Inc. (NASDAQ: APDN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APDN stands at 7.3M. In comparison, GH has a market cap of 23.9B. Regarding current trading prices, APDN is priced at $5.62 on the NASDAQ, while GH trades at $177.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APDN currently has a P/E ratio of -0.10, whereas GH's P/E ratio is -50.95. In terms of profitability, APDN's ROE is -7.23%, compared to GH's ROE of +2.11%. Regarding short-term risk, APDN is more volatile compared to GH. This indicates higher risk in terms of short-term price fluctuations for APDN.Check GH's competition here
Exact Sciences Corporation (NASDAQ: EXAS)
APDN vs EXAS Comparison October 2026
Applied DNA Sciences, Inc. (NASDAQ: APDN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APDN stands at 7.3M. In comparison, EXAS has a market cap of 20B. Regarding current trading prices, APDN is priced at $5.62 on the NASDAQ, while EXAS trades at $104.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APDN currently has a P/E ratio of -0.10, whereas EXAS's P/E ratio is -95.37. In terms of profitability, APDN's ROE is -7.23%, compared to EXAS's ROE of -0.09%. Regarding short-term risk, APDN is more volatile compared to EXAS. This indicates higher risk in terms of short-term price fluctuations for APDN.Check EXAS's competition here
Illumina, Inc. Common Stock Ex-distribution When-Issued (NASDAQ: ILMNV)
APDN vs ILMNV Comparison October 2026
Applied DNA Sciences, Inc. (NASDAQ: APDN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APDN stands at 7.3M. In comparison, ILMNV has a market cap of 17B. Regarding current trading prices, APDN is priced at $5.62 on the NASDAQ, while ILMNV trades at $107.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APDN currently has a P/E ratio of -0.10, whereas ILMNV's P/E ratio is N/A. In terms of profitability, APDN's ROE is -7.23%, compared to ILMNV's ROE of N/A. Regarding short-term risk, APDN is more volatile compared to ILMNV. This indicates higher risk in terms of short-term price fluctuations for APDN.Check ILMNV's competition here
Revvity, Inc. (NYSE: RVTY)
APDN vs RVTY Comparison October 2026
Applied DNA Sciences, Inc. (NASDAQ: APDN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APDN stands at 7.3M. In comparison, RVTY has a market cap of 16.9B. Regarding current trading prices, APDN is priced at $5.62 on the NASDAQ, while RVTY trades at $151.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APDN currently has a P/E ratio of -0.10, whereas RVTY's P/E ratio is 28.30. In terms of profitability, APDN's ROE is -7.23%, compared to RVTY's ROE of +0.03%. Regarding short-term risk, APDN is more volatile compared to RVTY. This indicates higher risk in terms of short-term price fluctuations for APDN.Check RVTY's competition here
Medpace Holdings, Inc. (NASDAQ: MEDP)
APDN vs MEDP Comparison October 2026
Applied DNA Sciences, Inc. (NASDAQ: APDN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APDN stands at 7.3M. In comparison, MEDP has a market cap of 16.7B. Regarding current trading prices, APDN is priced at $5.62 on the NASDAQ, while MEDP trades at $599.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APDN currently has a P/E ratio of -0.10, whereas MEDP's P/E ratio is 35.14. In terms of profitability, APDN's ROE is -7.23%, compared to MEDP's ROE of +1.10%. Regarding short-term risk, APDN is more volatile compared to MEDP. This indicates higher risk in terms of short-term price fluctuations for APDN.Check MEDP's competition here
PerkinElmer, Inc. (NYSE: PKI)
APDN vs PKI Comparison October 2026
Applied DNA Sciences, Inc. (NASDAQ: APDN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APDN stands at 7.3M. In comparison, PKI has a market cap of 14.5B. Regarding current trading prices, APDN is priced at $5.62 on the NASDAQ, while PKI trades at $115.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APDN currently has a P/E ratio of -0.10, whereas PKI's P/E ratio is 41.45. In terms of profitability, APDN's ROE is -7.23%, compared to PKI's ROE of +0.03%. Regarding short-term risk, APDN is more volatile compared to PKI. This indicates higher risk in terms of short-term price fluctuations for APDN.Check PKI's competition here
Charles River Laboratories International, Inc. (NYSE: CRL)
APDN vs CRL Comparison October 2026
Applied DNA Sciences, Inc. (NASDAQ: APDN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APDN stands at 7.3M. In comparison, CRL has a market cap of 14B. Regarding current trading prices, APDN is priced at $5.62 on the NASDAQ, while CRL trades at $290.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APDN currently has a P/E ratio of -0.10, whereas CRL's P/E ratio is 29.31. In terms of profitability, APDN's ROE is -7.23%, compared to CRL's ROE of -0.08%. Regarding short-term risk, APDN is more volatile compared to CRL. This indicates higher risk in terms of short-term price fluctuations for APDN.Check CRL's competition here
ICON Public Limited Company (NASDAQ: ICLR)
APDN vs ICLR Comparison October 2026
Applied DNA Sciences, Inc. (NASDAQ: APDN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APDN stands at 7.3M. In comparison, ICLR has a market cap of 12.4B. Regarding current trading prices, APDN is priced at $5.62 on the NASDAQ, while ICLR trades at $162.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APDN currently has a P/E ratio of -0.10, whereas ICLR's P/E ratio is 13.22. In terms of profitability, APDN's ROE is -7.23%, compared to ICLR's ROE of +0.04%. Regarding short-term risk, APDN is more volatile compared to ICLR. This indicates higher risk in terms of short-term price fluctuations for APDN.Check ICLR's competition here
Qiagen N.V. (NYSE: QGEN)
APDN vs QGEN Comparison October 2026
Applied DNA Sciences, Inc. (NASDAQ: APDN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APDN stands at 7.3M. In comparison, QGEN has a market cap of 9.2B. Regarding current trading prices, APDN is priced at $5.62 on the NASDAQ, while QGEN trades at $44.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APDN currently has a P/E ratio of -0.10, whereas QGEN's P/E ratio is 18.49. In terms of profitability, APDN's ROE is -7.23%, compared to QGEN's ROE of +0.12%. Regarding short-term risk, APDN is more volatile compared to QGEN. This indicates higher risk in terms of short-term price fluctuations for APDN.Check QGEN's competition here
GRAIL Inc. (NASDAQ: GRAL)
APDN vs GRAL Comparison October 2026
Applied DNA Sciences, Inc. (NASDAQ: APDN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APDN stands at 7.3M. In comparison, GRAL has a market cap of 5.7B. Regarding current trading prices, APDN is priced at $5.62 on the NASDAQ, while GRAL trades at $143.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APDN currently has a P/E ratio of -0.10, whereas GRAL's P/E ratio is -13.60. In terms of profitability, APDN's ROE is -7.23%, compared to GRAL's ROE of -0.16%. Regarding short-term risk, APDN is more volatile compared to GRAL. This indicates higher risk in terms of short-term price fluctuations for APDN.Check GRAL's competition here
RadNet, Inc. (NASDAQ: RDNT)
APDN vs RDNT Comparison October 2026
Applied DNA Sciences, Inc. (NASDAQ: APDN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APDN stands at 7.3M. In comparison, RDNT has a market cap of 5.5B. Regarding current trading prices, APDN is priced at $5.62 on the NASDAQ, while RDNT trades at $69.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APDN currently has a P/E ratio of -0.10, whereas RDNT's P/E ratio is 152.02. In terms of profitability, APDN's ROE is -7.23%, compared to RDNT's ROE of -0.02%. Regarding short-term risk, APDN is more volatile compared to RDNT. This indicates higher risk in terms of short-term price fluctuations for APDN.Check RDNT's competition here
Sotera Health Company (NASDAQ: SHC)
APDN vs SHC Comparison October 2026
Applied DNA Sciences, Inc. (NASDAQ: APDN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APDN stands at 7.3M. In comparison, SHC has a market cap of 5.2B. Regarding current trading prices, APDN is priced at $5.62 on the NASDAQ, while SHC trades at $18.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APDN currently has a P/E ratio of -0.10, whereas SHC's P/E ratio is 18.98. In terms of profitability, APDN's ROE is -7.23%, compared to SHC's ROE of +0.27%. Regarding short-term risk, APDN is more volatile compared to SHC. This indicates higher risk in terms of short-term price fluctuations for APDN.Check SHC's competition here
BillionToOne, Inc. (NASDAQ: BLLN)
APDN vs BLLN Comparison October 2026
Applied DNA Sciences, Inc. (NASDAQ: APDN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APDN stands at 7.3M. In comparison, BLLN has a market cap of 4.9B. Regarding current trading prices, APDN is priced at $5.62 on the NASDAQ, while BLLN trades at $105.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APDN currently has a P/E ratio of -0.10, whereas BLLN's P/E ratio is 151.29. In terms of profitability, APDN's ROE is -7.23%, compared to BLLN's ROE of +0.08%. Regarding short-term risk, APDN is more volatile compared to BLLN. This indicates higher risk in terms of short-term price fluctuations for APDN.Check BLLN's competition here
Syneos Health, Inc. (NASDAQ: SYNH)
APDN vs SYNH Comparison October 2026
Applied DNA Sciences, Inc. (NASDAQ: APDN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APDN stands at 7.3M. In comparison, SYNH has a market cap of 4.5B. Regarding current trading prices, APDN is priced at $5.62 on the NASDAQ, while SYNH trades at $42.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APDN currently has a P/E ratio of -0.10, whereas SYNH's P/E ratio is 61.40. In terms of profitability, APDN's ROE is -7.23%, compared to SYNH's ROE of +0.08%. Regarding short-term risk, APDN is more volatile compared to SYNH. This indicates higher risk in terms of short-term price fluctuations for APDN.Check SYNH's competition here
Veracyte, Inc. (NASDAQ: VCYT)
APDN vs VCYT Comparison October 2026
Applied DNA Sciences, Inc. (NASDAQ: APDN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APDN stands at 7.3M. In comparison, VCYT has a market cap of 3.7B. Regarding current trading prices, APDN is priced at $5.62 on the NASDAQ, while VCYT trades at $45.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APDN currently has a P/E ratio of -0.10, whereas VCYT's P/E ratio is 22.91. In terms of profitability, APDN's ROE is -7.23%, compared to VCYT's ROE of +0.09%. Regarding short-term risk, APDN is more volatile compared to VCYT. This indicates higher risk in terms of short-term price fluctuations for APDN.Check VCYT's competition here
CareDx, Inc (NASDAQ: CDNA)
APDN vs CDNA Comparison October 2026
Applied DNA Sciences, Inc. (NASDAQ: APDN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APDN stands at 7.3M. In comparison, CDNA has a market cap of 3.5B. Regarding current trading prices, APDN is priced at $5.62 on the NASDAQ, while CDNA trades at $67.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APDN currently has a P/E ratio of -0.10, whereas CDNA's P/E ratio is 79.94. In terms of profitability, APDN's ROE is -7.23%, compared to CDNA's ROE of +0.33%. Regarding short-term risk, APDN is more volatile compared to CDNA. This indicates higher risk in terms of short-term price fluctuations for APDN.Check CDNA's competition here
Olink Holding AB (publ) (NASDAQ: OLK)
APDN vs OLK Comparison October 2026
Applied DNA Sciences, Inc. (NASDAQ: APDN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APDN stands at 7.3M. In comparison, OLK has a market cap of 3.2B. Regarding current trading prices, APDN is priced at $5.62 on the NASDAQ, while OLK trades at $26.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APDN currently has a P/E ratio of -0.10, whereas OLK's P/E ratio is -96.59. In terms of profitability, APDN's ROE is -7.23%, compared to OLK's ROE of -0.07%. Regarding short-term risk, APDN is more volatile compared to OLK. This indicates higher risk in terms of short-term price fluctuations for APDN.Check OLK's competition here
GeneDx Holdings Corp. (NASDAQ: WGS)
APDN vs WGS Comparison October 2026
Applied DNA Sciences, Inc. (NASDAQ: APDN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APDN stands at 7.3M. In comparison, WGS has a market cap of 2.2B. Regarding current trading prices, APDN is priced at $5.62 on the NASDAQ, while WGS trades at $73.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APDN currently has a P/E ratio of -0.10, whereas WGS's P/E ratio is 203.03. In terms of profitability, APDN's ROE is -7.23%, compared to WGS's ROE of -0.39%. Regarding short-term risk, APDN is more volatile compared to WGS. This indicates higher risk in terms of short-term price fluctuations for APDN.Check WGS's competition here
Personalis, Inc. (NASDAQ: PSNL)
APDN vs PSNL Comparison October 2026
Applied DNA Sciences, Inc. (NASDAQ: APDN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APDN stands at 7.3M. In comparison, PSNL has a market cap of 1.7B. Regarding current trading prices, APDN is priced at $5.62 on the NASDAQ, while PSNL trades at $16.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APDN currently has a P/E ratio of -0.10, whereas PSNL's P/E ratio is -14.94. In terms of profitability, APDN's ROE is -7.23%, compared to PSNL's ROE of -0.46%. Regarding short-term risk, APDN is more volatile compared to PSNL. This indicates higher risk in terms of short-term price fluctuations for APDN.Check PSNL's competition here
OPKO Health, Inc. (NASDAQ: OPK)
APDN vs OPK Comparison October 2026
Applied DNA Sciences, Inc. (NASDAQ: APDN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APDN stands at 7.3M. In comparison, OPK has a market cap of 1.2B. Regarding current trading prices, APDN is priced at $5.62 on the NASDAQ, while OPK trades at $1.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APDN currently has a P/E ratio of -0.10, whereas OPK's P/E ratio is -5.78. In terms of profitability, APDN's ROE is -7.23%, compared to OPK's ROE of -0.06%. Regarding short-term risk, APDN is more volatile compared to OPK. This indicates higher risk in terms of short-term price fluctuations for APDN.Check OPK's competition here
Castle Biosciences, Inc. (NASDAQ: CSTL)
APDN vs CSTL Comparison October 2026
Applied DNA Sciences, Inc. (NASDAQ: APDN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APDN stands at 7.3M. In comparison, CSTL has a market cap of 1.1B. Regarding current trading prices, APDN is priced at $5.62 on the NASDAQ, while CSTL trades at $35.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APDN currently has a P/E ratio of -0.10, whereas CSTL's P/E ratio is -53.88. In terms of profitability, APDN's ROE is -7.23%, compared to CSTL's ROE of -0.04%. Regarding short-term risk, APDN is more volatile compared to CSTL. This indicates higher risk in terms of short-term price fluctuations for APDN.Check CSTL's competition here
Fulgent Genetics, Inc. (NASDAQ: FLGT)
APDN vs FLGT Comparison October 2026
Applied DNA Sciences, Inc. (NASDAQ: APDN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APDN stands at 7.3M. In comparison, FLGT has a market cap of 610M. Regarding current trading prices, APDN is priced at $5.62 on the NASDAQ, while FLGT trades at $21.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APDN currently has a P/E ratio of -0.10, whereas FLGT's P/E ratio is 2148.00. In terms of profitability, APDN's ROE is -7.23%, compared to FLGT's ROE of -0.08%. Regarding short-term risk, APDN is more volatile compared to FLGT. This indicates higher risk in terms of short-term price fluctuations for APDN.Check FLGT's competition here
GRAIL, Inc. Common Stock (NASDAQ: GRALV)
APDN vs GRALV Comparison October 2026
Applied DNA Sciences, Inc. (NASDAQ: APDN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APDN stands at 7.3M. In comparison, GRALV has a market cap of 579.4M. Regarding current trading prices, APDN is priced at $5.62 on the NASDAQ, while GRALV trades at $18.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APDN currently has a P/E ratio of -0.10, whereas GRALV's P/E ratio is N/A. In terms of profitability, APDN's ROE is -7.23%, compared to GRALV's ROE of N/A. Regarding short-term risk, APDN is more volatile compared to GRALV. This indicates higher risk in terms of short-term price fluctuations for APDN.Check GRALV's competition here
NeoGenomics, Inc. (NASDAQ: NEO)
APDN vs NEO Comparison October 2026
Applied DNA Sciences, Inc. (NASDAQ: APDN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APDN stands at 7.3M. In comparison, NEO has a market cap of 474.6M. Regarding current trading prices, APDN is priced at $5.62 on the NASDAQ, while NEO trades at $18.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APDN currently has a P/E ratio of -0.10, whereas NEO's P/E ratio is 142.08. In terms of profitability, APDN's ROE is -7.23%, compared to NEO's ROE of -0.06%. Regarding short-term risk, APDN is more volatile compared to NEO. This indicates higher risk in terms of short-term price fluctuations for APDN.Check NEO's competition here
Myriad Genetics, Inc. (NASDAQ: MYGN)
APDN vs MYGN Comparison October 2026
Applied DNA Sciences, Inc. (NASDAQ: APDN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APDN stands at 7.3M. In comparison, MYGN has a market cap of 428.8M. Regarding current trading prices, APDN is priced at $5.62 on the NASDAQ, while MYGN trades at $4.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APDN currently has a P/E ratio of -0.10, whereas MYGN's P/E ratio is -34.92. In terms of profitability, APDN's ROE is -7.23%, compared to MYGN's ROE of -0.33%. Regarding short-term risk, APDN is more volatile compared to MYGN. This indicates higher risk in terms of short-term price fluctuations for APDN.Check MYGN's competition here
Global Cord Blood Corporation (NYSE: CO)
APDN vs CO Comparison October 2026
Applied DNA Sciences, Inc. (NASDAQ: APDN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APDN stands at 7.3M. In comparison, CO has a market cap of 400.1M. Regarding current trading prices, APDN is priced at $5.62 on the NASDAQ, while CO trades at $2.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APDN currently has a P/E ratio of -0.10, whereas CO's P/E ratio is 5.06. In terms of profitability, APDN's ROE is -7.23%, compared to CO's ROE of +0.11%. Regarding short-term risk, APDN is less volatile compared to CO. This indicates lower risk in terms of short-term price fluctuations for APDN.Check CO's competition here
Standard BioTools Inc. (NASDAQ: FLDM)
APDN vs FLDM Comparison October 2026
Applied DNA Sciences, Inc. (NASDAQ: APDN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APDN stands at 7.3M. In comparison, FLDM has a market cap of 294.2M. Regarding current trading prices, APDN is priced at $5.62 on the NASDAQ, while FLDM trades at $3.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APDN currently has a P/E ratio of -0.10, whereas FLDM's P/E ratio is -4.74. In terms of profitability, APDN's ROE is -7.23%, compared to FLDM's ROE of +0.18%. Regarding short-term risk, APDN is more volatile compared to FLDM. This indicates higher risk in terms of short-term price fluctuations for APDN.Check FLDM's competition here
Biodesix, Inc. (NASDAQ: BDSX)
APDN vs BDSX Comparison October 2026
Applied DNA Sciences, Inc. (NASDAQ: APDN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APDN stands at 7.3M. In comparison, BDSX has a market cap of 225.6M. Regarding current trading prices, APDN is priced at $5.62 on the NASDAQ, while BDSX trades at $27.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APDN currently has a P/E ratio of -0.10, whereas BDSX's P/E ratio is -8.74. In terms of profitability, APDN's ROE is -7.23%, compared to BDSX's ROE of -7.88%. Regarding short-term risk, APDN is more volatile compared to BDSX. This indicates higher risk in terms of short-term price fluctuations for APDN.Check BDSX's competition here
Exagen Inc. (NASDAQ: XGN)
APDN vs XGN Comparison October 2026
Applied DNA Sciences, Inc. (NASDAQ: APDN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APDN stands at 7.3M. In comparison, XGN has a market cap of 197.4M. Regarding current trading prices, APDN is priced at $5.62 on the NASDAQ, while XGN trades at $8.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APDN currently has a P/E ratio of -0.10, whereas XGN's P/E ratio is -10.09. In terms of profitability, APDN's ROE is -7.23%, compared to XGN's ROE of -1.22%. Regarding short-term risk, APDN is more volatile compared to XGN. This indicates higher risk in terms of short-term price fluctuations for APDN.Check XGN's competition here
Freenome, Inc. (NASDAQ: FRNM)
APDN vs FRNM Comparison October 2026
Applied DNA Sciences, Inc. (NASDAQ: APDN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APDN stands at 7.3M. In comparison, FRNM has a market cap of 133.1M. Regarding current trading prices, APDN is priced at $5.62 on the NASDAQ, while FRNM trades at $16.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APDN currently has a P/E ratio of -0.10, whereas FRNM's P/E ratio is N/A. In terms of profitability, APDN's ROE is -7.23%, compared to FRNM's ROE of N/A. Regarding short-term risk, APDN is more volatile compared to FRNM. This indicates higher risk in terms of short-term price fluctuations for APDN.Check FRNM's competition here
Genetron Holdings Limited (NASDAQ: GTH)
APDN vs GTH Comparison October 2026
Applied DNA Sciences, Inc. (NASDAQ: APDN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APDN stands at 7.3M. In comparison, GTH has a market cap of 127.3M. Regarding current trading prices, APDN is priced at $5.62 on the NASDAQ, while GTH trades at $4.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APDN currently has a P/E ratio of -0.10, whereas GTH's P/E ratio is -1.11. In terms of profitability, APDN's ROE is -7.23%, compared to GTH's ROE of -1.01%. Regarding short-term risk, APDN is more volatile compared to GTH. This indicates higher risk in terms of short-term price fluctuations for APDN.Check GTH's competition here
Genetic Technologies Limited (NASDAQ: GENE)
APDN vs GENE Comparison October 2026
Applied DNA Sciences, Inc. (NASDAQ: APDN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APDN stands at 7.3M. In comparison, GENE has a market cap of 111.2M. Regarding current trading prices, APDN is priced at $5.62 on the NASDAQ, while GENE trades at $0.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APDN currently has a P/E ratio of -0.10, whereas GENE's P/E ratio is -38.25. In terms of profitability, APDN's ROE is -7.23%, compared to GENE's ROE of -1.85%. Regarding short-term risk, APDN is more volatile compared to GENE. This indicates higher risk in terms of short-term price fluctuations for APDN.Check GENE's competition here
Insight Molecular Diagnostics Inc. (NASDAQ: IMDX)
APDN vs IMDX Comparison October 2026
Applied DNA Sciences, Inc. (NASDAQ: APDN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APDN stands at 7.3M. In comparison, IMDX has a market cap of 111.1M. Regarding current trading prices, APDN is priced at $5.62 on the NASDAQ, while IMDX trades at $3.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APDN currently has a P/E ratio of -0.10, whereas IMDX's P/E ratio is -2.31. In terms of profitability, APDN's ROE is -7.23%, compared to IMDX's ROE of +2.72%. Regarding short-term risk, APDN is more volatile compared to IMDX. This indicates higher risk in terms of short-term price fluctuations for APDN.Check IMDX's competition here
Sera Prognostics, Inc. (NASDAQ: SERA)
APDN vs SERA Comparison October 2026
Applied DNA Sciences, Inc. (NASDAQ: APDN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APDN stands at 7.3M. In comparison, SERA has a market cap of 79.1M. Regarding current trading prices, APDN is priced at $5.62 on the NASDAQ, while SERA trades at $2.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APDN currently has a P/E ratio of -0.10, whereas SERA's P/E ratio is -3.18. In terms of profitability, APDN's ROE is -7.23%, compared to SERA's ROE of -0.47%. Regarding short-term risk, APDN is more volatile compared to SERA. This indicates higher risk in terms of short-term price fluctuations for APDN.Check SERA's competition here
Precipio, Inc. (NASDAQ: PRPO)
APDN vs PRPO Comparison October 2026
Applied DNA Sciences, Inc. (NASDAQ: APDN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APDN stands at 7.3M. In comparison, PRPO has a market cap of 41.3M. Regarding current trading prices, APDN is priced at $5.62 on the NASDAQ, while PRPO trades at $23.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APDN currently has a P/E ratio of -0.10, whereas PRPO's P/E ratio is -35.58. In terms of profitability, APDN's ROE is -7.23%, compared to PRPO's ROE of -0.08%. Regarding short-term risk, APDN is more volatile compared to PRPO. This indicates higher risk in terms of short-term price fluctuations for APDN.Check PRPO's competition here
Quantum Cyber N.V. (NASDAQ: QUCY)
APDN vs QUCY Comparison October 2026
Applied DNA Sciences, Inc. (NASDAQ: APDN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APDN stands at 7.3M. In comparison, QUCY has a market cap of 30.5M. Regarding current trading prices, APDN is priced at $5.62 on the NASDAQ, while QUCY trades at $1.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APDN currently has a P/E ratio of -0.10, whereas QUCY's P/E ratio is -0.06. In terms of profitability, APDN's ROE is -7.23%, compared to QUCY's ROE of -3.65%. Regarding short-term risk, APDN is more volatile compared to QUCY. This indicates higher risk in terms of short-term price fluctuations for APDN.Check QUCY's competition here
MDxHealth S.A. (NASDAQ: MDXH)
APDN vs MDXH Comparison October 2026
Applied DNA Sciences, Inc. (NASDAQ: APDN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APDN stands at 7.3M. In comparison, MDXH has a market cap of 29.3M. Regarding current trading prices, APDN is priced at $5.62 on the NASDAQ, while MDXH trades at $0.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APDN currently has a P/E ratio of -0.10, whereas MDXH's P/E ratio is -0.78. In terms of profitability, APDN's ROE is -7.23%, compared to MDXH's ROE of +1.43%. Regarding short-term risk, APDN is more volatile compared to MDXH. This indicates higher risk in terms of short-term price fluctuations for APDN.Check MDXH's competition here
Akumin Inc. (NASDAQ: AKU)
APDN vs AKU Comparison October 2026
Applied DNA Sciences, Inc. (NASDAQ: APDN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APDN stands at 7.3M. In comparison, AKU has a market cap of 26.3M. Regarding current trading prices, APDN is priced at $5.62 on the NASDAQ, while AKU trades at $0.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APDN currently has a P/E ratio of -0.10, whereas AKU's P/E ratio is -0.13. In terms of profitability, APDN's ROE is -7.23%, compared to AKU's ROE of -5.32%. Regarding short-term risk, APDN is more volatile compared to AKU. This indicates higher risk in terms of short-term price fluctuations for APDN.Check AKU's competition here
Burning Rock Biotech Limited (NASDAQ: BNR)
APDN vs BNR Comparison October 2026
Applied DNA Sciences, Inc. (NASDAQ: APDN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APDN stands at 7.3M. In comparison, BNR has a market cap of 17.3M. Regarding current trading prices, APDN is priced at $5.62 on the NASDAQ, while BNR trades at $16.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APDN currently has a P/E ratio of -0.10, whereas BNR's P/E ratio is -18.84. In terms of profitability, APDN's ROE is -7.23%, compared to BNR's ROE of -0.13%. Regarding short-term risk, APDN is more volatile compared to BNR. This indicates higher risk in terms of short-term price fluctuations for APDN.Check BNR's competition here
Chembio Diagnostics, Inc. (NASDAQ: CEMI)
APDN vs CEMI Comparison October 2026
Applied DNA Sciences, Inc. (NASDAQ: APDN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APDN stands at 7.3M. In comparison, CEMI has a market cap of 16.7M. Regarding current trading prices, APDN is priced at $5.62 on the NASDAQ, while CEMI trades at $0.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APDN currently has a P/E ratio of -0.10, whereas CEMI's P/E ratio is -0.63. In terms of profitability, APDN's ROE is -7.23%, compared to CEMI's ROE of -0.89%. Regarding short-term risk, APDN is more volatile compared to CEMI. This indicates higher risk in terms of short-term price fluctuations for APDN.Check CEMI's competition here
Enzo Biochem, Inc. (NYSE: ENZ)
APDN vs ENZ Comparison October 2026
Applied DNA Sciences, Inc. (NASDAQ: APDN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APDN stands at 7.3M. In comparison, ENZ has a market cap of 16.4M. Regarding current trading prices, APDN is priced at $5.62 on the NASDAQ, while ENZ trades at $0.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APDN currently has a P/E ratio of -0.10, whereas ENZ's P/E ratio is -2.24. In terms of profitability, APDN's ROE is -7.23%, compared to ENZ's ROE of -0.39%. Regarding short-term risk, APDN is less volatile compared to ENZ. This indicates lower risk in terms of short-term price fluctuations for APDN.Check ENZ's competition here
Psychemedics Corporation (NASDAQ: PMD)
APDN vs PMD Comparison October 2026
Applied DNA Sciences, Inc. (NASDAQ: APDN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APDN stands at 7.3M. In comparison, PMD has a market cap of 15.6M. Regarding current trading prices, APDN is priced at $5.62 on the NASDAQ, while PMD trades at $2.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APDN currently has a P/E ratio of -0.10, whereas PMD's P/E ratio is -5.24. In terms of profitability, APDN's ROE is -7.23%, compared to PMD's ROE of -0.32%. Regarding short-term risk, APDN is more volatile compared to PMD. This indicates higher risk in terms of short-term price fluctuations for APDN.Check PMD's competition here
23andMe Holding Co. (NASDAQ: ME)
APDN vs ME Comparison October 2026
Applied DNA Sciences, Inc. (NASDAQ: APDN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APDN stands at 7.3M. In comparison, ME has a market cap of 15.3M. Regarding current trading prices, APDN is priced at $5.62 on the NASDAQ, while ME trades at $0.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APDN currently has a P/E ratio of -0.10, whereas ME's P/E ratio is -0.03. In terms of profitability, APDN's ROE is -7.23%, compared to ME's ROE of -42.03%. Regarding short-term risk, APDN is more volatile compared to ME. This indicates higher risk in terms of short-term price fluctuations for APDN.Check ME's competition here
Mainz Biomed B.V. (NASDAQ: MYNZ)
APDN vs MYNZ Comparison October 2026
Applied DNA Sciences, Inc. (NASDAQ: APDN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APDN stands at 7.3M. In comparison, MYNZ has a market cap of 14.7M. Regarding current trading prices, APDN is priced at $5.62 on the NASDAQ, while MYNZ trades at $3.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APDN currently has a P/E ratio of -0.10, whereas MYNZ's P/E ratio is -1.33. In terms of profitability, APDN's ROE is -7.23%, compared to MYNZ's ROE of -1.80%. Regarding short-term risk, APDN is more volatile compared to MYNZ. This indicates higher risk in terms of short-term price fluctuations for APDN.Check MYNZ's competition here
bioAffinity Technologies, Inc. (NASDAQ: BIAFW)
APDN vs BIAFW Comparison October 2026
Applied DNA Sciences, Inc. (NASDAQ: APDN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APDN stands at 7.3M. In comparison, BIAFW has a market cap of 11.8M. Regarding current trading prices, APDN is priced at $5.62 on the NASDAQ, while BIAFW trades at $0.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APDN currently has a P/E ratio of -0.10, whereas BIAFW's P/E ratio is 1.25. In terms of profitability, APDN's ROE is -7.23%, compared to BIAFW's ROE of -2.57%. Regarding short-term risk, APDN is less volatile compared to BIAFW. This indicates lower risk in terms of short-term price fluctuations for APDN.Check BIAFW's competition here
Check-Cap Ltd. (NASDAQ: CHEK)
APDN vs CHEK Comparison October 2026
Applied DNA Sciences, Inc. (NASDAQ: APDN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APDN stands at 7.3M. In comparison, CHEK has a market cap of 10.9M. Regarding current trading prices, APDN is priced at $5.62 on the NASDAQ, while CHEK trades at $1.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APDN currently has a P/E ratio of -0.10, whereas CHEK's P/E ratio is -0.43. In terms of profitability, APDN's ROE is -7.23%, compared to CHEK's ROE of -2.26%. Regarding short-term risk, APDN is more volatile compared to CHEK. This indicates higher risk in terms of short-term price fluctuations for APDN.Check CHEK's competition here
Centogene N.V. (NASDAQ: CNTG)
APDN vs CNTG Comparison October 2026
Applied DNA Sciences, Inc. (NASDAQ: APDN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APDN stands at 7.3M. In comparison, CNTG has a market cap of 9.4M. Regarding current trading prices, APDN is priced at $5.62 on the NASDAQ, while CNTG trades at $0.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APDN currently has a P/E ratio of -0.10, whereas CNTG's P/E ratio is -0.23. In terms of profitability, APDN's ROE is -7.23%, compared to CNTG's ROE of +3.98%. Regarding short-term risk, APDN is more volatile compared to CNTG. This indicates higher risk in terms of short-term price fluctuations for APDN.Check CNTG's competition here
Advanced Biomed Inc. Common Stock (NASDAQ: ADVB)
APDN vs ADVB Comparison October 2026
Applied DNA Sciences, Inc. (NASDAQ: APDN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APDN stands at 7.3M. In comparison, ADVB has a market cap of 9.3M. Regarding current trading prices, APDN is priced at $5.62 on the NASDAQ, while ADVB trades at $6.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APDN currently has a P/E ratio of -0.10, whereas ADVB's P/E ratio is -61.00. In terms of profitability, APDN's ROE is -7.23%, compared to ADVB's ROE of -0.21%. Regarding short-term risk, APDN is more volatile compared to ADVB. This indicates higher risk in terms of short-term price fluctuations for APDN.Check ADVB's competition here
ENDRA Life Sciences Inc. (NASDAQ: NDRA)
APDN vs NDRA Comparison October 2026
Applied DNA Sciences, Inc. (NASDAQ: APDN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APDN stands at 7.3M. In comparison, NDRA has a market cap of 7.7M. Regarding current trading prices, APDN is priced at $5.62 on the NASDAQ, while NDRA trades at $6.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APDN currently has a P/E ratio of -0.10, whereas NDRA's P/E ratio is -0.90. In terms of profitability, APDN's ROE is -7.23%, compared to NDRA's ROE of -2.25%. Regarding short-term risk, APDN is more volatile compared to NDRA. This indicates higher risk in terms of short-term price fluctuations for APDN.Check NDRA's competition here
Invitae Corporation (NYSE: NVTA)
APDN vs NVTA Comparison October 2026
Applied DNA Sciences, Inc. (NASDAQ: APDN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APDN stands at 7.3M. In comparison, NVTA has a market cap of 5.4M. Regarding current trading prices, APDN is priced at $5.62 on the NASDAQ, while NVTA trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APDN currently has a P/E ratio of -0.10, whereas NVTA's P/E ratio is -0.00. In terms of profitability, APDN's ROE is -7.23%, compared to NVTA's ROE of -2.02%. Regarding short-term risk, APDN is less volatile compared to NVTA. This indicates lower risk in terms of short-term price fluctuations for APDN.Check NVTA's competition here
LumiraDx Limited (NASDAQ: LMDX)
APDN vs LMDX Comparison October 2026
Applied DNA Sciences, Inc. (NASDAQ: APDN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APDN stands at 7.3M. In comparison, LMDX has a market cap of 5.1M. Regarding current trading prices, APDN is priced at $5.62 on the NASDAQ, while LMDX trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APDN currently has a P/E ratio of -0.10, whereas LMDX's P/E ratio is -0.01. In terms of profitability, APDN's ROE is -7.23%, compared to LMDX's ROE of -15.58%. Regarding short-term risk, APDN is less volatile compared to LMDX. This indicates lower risk in terms of short-term price fluctuations for APDN.Check LMDX's competition here
LumiraDx Limited (NASDAQ: LMDXW)
APDN vs LMDXW Comparison October 2026
Applied DNA Sciences, Inc. (NASDAQ: APDN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APDN stands at 7.3M. In comparison, LMDXW has a market cap of 5.1M. Regarding current trading prices, APDN is priced at $5.62 on the NASDAQ, while LMDXW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APDN currently has a P/E ratio of -0.10, whereas LMDXW's P/E ratio is -0.00. In terms of profitability, APDN's ROE is -7.23%, compared to LMDXW's ROE of -15.58%. Regarding short-term risk, APDN is less volatile compared to LMDXW. This indicates lower risk in terms of short-term price fluctuations for APDN.Check LMDXW's competition here
DermTech, Inc. (NASDAQ: DMTK)
APDN vs DMTK Comparison October 2026
Applied DNA Sciences, Inc. (NASDAQ: APDN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APDN stands at 7.3M. In comparison, DMTK has a market cap of 3.3M. Regarding current trading prices, APDN is priced at $5.62 on the NASDAQ, while DMTK trades at $0.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APDN currently has a P/E ratio of -0.10, whereas DMTK's P/E ratio is -0.04. In terms of profitability, APDN's ROE is -7.23%, compared to DMTK's ROE of -1.06%. Regarding short-term risk, APDN is more volatile compared to DMTK. This indicates higher risk in terms of short-term price fluctuations for APDN.Check DMTK's competition here
Inotiv, Inc. (NASDAQ: NOTV)
APDN vs NOTV Comparison October 2026
Applied DNA Sciences, Inc. (NASDAQ: APDN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APDN stands at 7.3M. In comparison, NOTV has a market cap of 2.8M. Regarding current trading prices, APDN is priced at $5.62 on the NASDAQ, while NOTV trades at $0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APDN currently has a P/E ratio of -0.10, whereas NOTV's P/E ratio is -0.03. In terms of profitability, APDN's ROE is -7.23%, compared to NOTV's ROE of -0.75%. Regarding short-term risk, APDN is more volatile compared to NOTV. This indicates higher risk in terms of short-term price fluctuations for APDN.Check NOTV's competition here
iSpecimen Inc. (NASDAQ: ISPC)
APDN vs ISPC Comparison October 2026
Applied DNA Sciences, Inc. (NASDAQ: APDN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APDN stands at 7.3M. In comparison, ISPC has a market cap of 2.6M. Regarding current trading prices, APDN is priced at $5.62 on the NASDAQ, while ISPC trades at $1.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APDN currently has a P/E ratio of -0.10, whereas ISPC's P/E ratio is -0.03. In terms of profitability, APDN's ROE is -7.23%, compared to ISPC's ROE of -5.24%. Regarding short-term risk, APDN is more volatile compared to ISPC. This indicates higher risk in terms of short-term price fluctuations for APDN.Check ISPC's competition here
bioAffinity Technologies, Inc. (NASDAQ: BIAF)
APDN vs BIAF Comparison October 2026
Applied DNA Sciences, Inc. (NASDAQ: APDN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APDN stands at 7.3M. In comparison, BIAF has a market cap of 2.5M. Regarding current trading prices, APDN is priced at $5.62 on the NASDAQ, while BIAF trades at $6.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APDN currently has a P/E ratio of -0.10, whereas BIAF's P/E ratio is -0.71. In terms of profitability, APDN's ROE is -7.23%, compared to BIAF's ROE of -2.57%. Regarding short-term risk, APDN is more volatile compared to BIAF. This indicates higher risk in terms of short-term price fluctuations for APDN.Check BIAF's competition here
SeqLL Inc. (NASDAQ: SQL)
APDN vs SQL Comparison October 2026
Applied DNA Sciences, Inc. (NASDAQ: APDN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APDN stands at 7.3M. In comparison, SQL has a market cap of 2.5M. Regarding current trading prices, APDN is priced at $5.62 on the NASDAQ, while SQL trades at $6.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APDN currently has a P/E ratio of -0.10, whereas SQL's P/E ratio is -0.40. In terms of profitability, APDN's ROE is -7.23%, compared to SQL's ROE of -30.46%. Regarding short-term risk, APDN is more volatile compared to SQL. This indicates higher risk in terms of short-term price fluctuations for APDN.Check SQL's competition here
Aspira Women's Health Inc. (NASDAQ: AWH)
APDN vs AWH Comparison October 2026
Applied DNA Sciences, Inc. (NASDAQ: APDN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APDN stands at 7.3M. In comparison, AWH has a market cap of 2.5M. Regarding current trading prices, APDN is priced at $5.62 on the NASDAQ, while AWH trades at $0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APDN currently has a P/E ratio of -0.10, whereas AWH's P/E ratio is -0.09. In terms of profitability, APDN's ROE is -7.23%, compared to AWH's ROE of +1.62%. Regarding short-term risk, APDN is more volatile compared to AWH. This indicates higher risk in terms of short-term price fluctuations for APDN.Check AWH's competition here
HTG Molecular Diagnostics, Inc. (NASDAQ: HTGM)
APDN vs HTGM Comparison October 2026
Applied DNA Sciences, Inc. (NASDAQ: APDN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APDN stands at 7.3M. In comparison, HTGM has a market cap of 1.1M. Regarding current trading prices, APDN is priced at $5.62 on the NASDAQ, while HTGM trades at $0.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APDN currently has a P/E ratio of -0.10, whereas HTGM's P/E ratio is -0.03. In terms of profitability, APDN's ROE is -7.23%, compared to HTGM's ROE of -2.73%. Regarding short-term risk, APDN is more volatile compared to HTGM. This indicates higher risk in terms of short-term price fluctuations for APDN.Check HTGM's competition here
Biocept, Inc. (NASDAQ: BIOC)
APDN vs BIOC Comparison October 2026
Applied DNA Sciences, Inc. (NASDAQ: APDN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APDN stands at 7.3M. In comparison, BIOC has a market cap of 450.8K. Regarding current trading prices, APDN is priced at $5.62 on the NASDAQ, while BIOC trades at $0.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APDN currently has a P/E ratio of -0.10, whereas BIOC's P/E ratio is -0.01. In terms of profitability, APDN's ROE is -7.23%, compared to BIOC's ROE of -1.38%. Regarding short-term risk, APDN is more volatile compared to BIOC. This indicates higher risk in terms of short-term price fluctuations for APDN.Check BIOC's competition here
SeqLL Inc. (NASDAQ: SQLLW)
APDN vs SQLLW Comparison October 2026
Applied DNA Sciences, Inc. (NASDAQ: APDN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APDN stands at 7.3M. In comparison, SQLLW has a market cap of 179.6K. Regarding current trading prices, APDN is priced at $5.62 on the NASDAQ, while SQLLW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APDN currently has a P/E ratio of -0.10, whereas SQLLW's P/E ratio is -0.00. In terms of profitability, APDN's ROE is -7.23%, compared to SQLLW's ROE of -30.46%. Regarding short-term risk, APDN is less volatile compared to SQLLW. This indicates lower risk in terms of short-term price fluctuations for APDN.Check SQLLW's competition here
GeneDx Holdings Corp. (NASDAQ: WGSWW)
APDN vs WGSWW Comparison October 2026
Applied DNA Sciences, Inc. (NASDAQ: APDN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APDN stands at 7.3M. In comparison, WGSWW has a market cap of 5.8K. Regarding current trading prices, APDN is priced at $5.62 on the NASDAQ, while WGSWW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APDN currently has a P/E ratio of -0.10, whereas WGSWW's P/E ratio is -0.00. In terms of profitability, APDN's ROE is -7.23%, compared to WGSWW's ROE of -0.39%. Regarding short-term risk, APDN is more volatile compared to WGSWW. This indicates higher risk in terms of short-term price fluctuations for APDN.Check WGSWW's competition here
Ortho Clinical Diagnostics Holdings plc (NASDAQ: OCDX)
APDN vs OCDX Comparison October 2026
Applied DNA Sciences, Inc. (NASDAQ: APDN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APDN stands at 7.3M. In comparison, OCDX has a market cap of 0. Regarding current trading prices, APDN is priced at $5.62 on the NASDAQ, while OCDX trades at $17.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APDN currently has a P/E ratio of -0.10, whereas OCDX's P/E ratio is -42.28. In terms of profitability, APDN's ROE is -7.23%, compared to OCDX's ROE of +0.18%. Regarding short-term risk, APDN is more volatile compared to OCDX. This indicates higher risk in terms of short-term price fluctuations for APDN.Check OCDX's competition here
Danaher Corporation (NYSE: DHR-PA)
APDN vs DHR-PA Comparison October 2026
Applied DNA Sciences, Inc. (NASDAQ: APDN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APDN stands at 7.3M. In comparison, DHR-PA has a market cap of 0. Regarding current trading prices, APDN is priced at $5.62 on the NASDAQ, while DHR-PA trades at $1,841.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APDN currently has a P/E ratio of -0.10, whereas DHR-PA's P/E ratio is 233.57. In terms of profitability, APDN's ROE is -7.23%, compared to DHR-PA's ROE of +0.08%. Regarding short-term risk, APDN is more volatile compared to DHR-PA. This indicates higher risk in terms of short-term price fluctuations for APDN.Check DHR-PA's competition here
Check-Cap Ltd (NASDAQ: CHEKZ)
APDN vs CHEKZ Comparison October 2026
Applied DNA Sciences, Inc. (NASDAQ: APDN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APDN stands at 7.3M. In comparison, CHEKZ has a market cap of 0. Regarding current trading prices, APDN is priced at $5.62 on the NASDAQ, while CHEKZ trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APDN currently has a P/E ratio of -0.10, whereas CHEKZ's P/E ratio is N/A. In terms of profitability, APDN's ROE is -7.23%, compared to CHEKZ's ROE of +4.17%. Regarding short-term risk, APDN is less volatile compared to CHEKZ. This indicates lower risk in terms of short-term price fluctuations for APDN.Check CHEKZ's competition here
PAREXEL Intl Corp. (NASDAQ: PRXL)
APDN vs PRXL Comparison October 2026
Applied DNA Sciences, Inc. (NASDAQ: APDN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APDN stands at 7.3M. In comparison, PRXL has a market cap of 0. Regarding current trading prices, APDN is priced at $5.62 on the NASDAQ, while PRXL trades at $88.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APDN currently has a P/E ratio of -0.10, whereas PRXL's P/E ratio is 42.97. In terms of profitability, APDN's ROE is -7.23%, compared to PRXL's ROE of +0.17%. Regarding short-term risk, APDN is more volatile compared to PRXL. This indicates higher risk in terms of short-term price fluctuations for APDN.Check PRXL's competition here
BioNano Genomics, Inc. WT EXP 082123 (NASDAQ: BNGOW)
APDN vs BNGOW Comparison October 2026
Applied DNA Sciences, Inc. (NASDAQ: APDN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APDN stands at 7.3M. In comparison, BNGOW has a market cap of 0. Regarding current trading prices, APDN is priced at $5.62 on the NASDAQ, while BNGOW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APDN currently has a P/E ratio of -0.10, whereas BNGOW's P/E ratio is N/A. In terms of profitability, APDN's ROE is -7.23%, compared to BNGOW's ROE of -0.79%. Regarding short-term risk, APDN is less volatile compared to BNGOW. This indicates lower risk in terms of short-term price fluctuations for APDN.Check BNGOW's competition here
ENDRA Life Sciences Inc. Warrants (NASDAQ: NDRAW)
APDN vs NDRAW Comparison October 2026
Applied DNA Sciences, Inc. (NASDAQ: APDN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APDN stands at 7.3M. In comparison, NDRAW has a market cap of 0. Regarding current trading prices, APDN is priced at $5.62 on the NASDAQ, while NDRAW trades at $0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APDN currently has a P/E ratio of -0.10, whereas NDRAW's P/E ratio is N/A. In terms of profitability, APDN's ROE is -7.23%, compared to NDRAW's ROE of -2.25%. Regarding short-term risk, APDN is less volatile compared to NDRAW. This indicates lower risk in terms of short-term price fluctuations for APDN.Check NDRAW's competition here
23andMe Holding Co. (NASDAQ: MEUSW)
APDN vs MEUSW Comparison October 2026
Applied DNA Sciences, Inc. (NASDAQ: APDN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APDN stands at 7.3M. In comparison, MEUSW has a market cap of 0. Regarding current trading prices, APDN is priced at $5.62 on the NASDAQ, while MEUSW trades at $1.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APDN currently has a P/E ratio of -0.10, whereas MEUSW's P/E ratio is N/A. In terms of profitability, APDN's ROE is -7.23%, compared to MEUSW's ROE of -42.03%. Regarding short-term risk, APDN is less volatile compared to MEUSW. This indicates lower risk in terms of short-term price fluctuations for APDN.Check MEUSW's competition here